At the ECTRIMS Annual Congress in September, the results of several clinical trials were presented that aim to find new treatments for multiple sclerosis. While some trials were successful and some were not, we learn from every trial that is conducted, and the research community takes those learnings into future trials – from ideas on new ways to test different treatments to how the trial was designed.

Hear from a panel of researchers who were part of three different teams that presented clinical trial results at ECTRIMS.

Catch up now!

Watch the webcast below and keep scrolling to read more about the host and expert panel.

To change the language of the subtitles, click the settings toggle in the bottom right corner to watch the video with Spanish, French, Italian and Arabic subtitles.

Webcast Panel

Panelists

Jeremy Chataway, PhD

Dr. Chataway is a consultant neurologist based at the University College London Institute of Neurology. He qualified in medicine at Cambridge and Oxford Universities, and general medical training in London, specialising in neurology. He was awarded a PhD from Cambridge University. His area of research is in advanced clinical trial design in progressive MS, and he has a national and international reputation in this field. He leads a number of clinical trials in Progressive Multiple Sclerosis (MS-STAT2 and OCTOPUS).

Burhan Chaudry, MD

Dr. Chaudry is the Medical Director and Senior Clinical Trial Physician, Neurosciences, for Bristol Myers Squibb. He has been integral to patient treatment for various patients within a neurology clinic, as well as driving clinical trial development across the world. He is currently a member of the steering committee and patient advisory committee for the Deliver MS Clinical Trial, which involves multiple enrollment sites worldwide including the US and UK.

Patrick Vermersch, MD, PhD

Prof. Vermersch is the Director of the graduate school for biology and health at the University of Lille in France, which deals with MS and other neuroinflammatory diseases. In 2000, he helped create the first MS network in northern France to improve both care and research in MS.  His current areas of interest are prognostic markers of MS and neuroimmunology in general, and he has published almost 400 scientific papers as author or co-author.

Host

Kathy Smith

Kathy is a pharmacologist and worked in the pharmaceutical industry in Research, Clinical Development and Strategy for over 25 years. She has worked in a professional capacity with the National MS Society’s Research (USA) on key strategic research efforts and has also provided expertise to the International Progressive MS Alliance. Kathy is a passionate advocate and fundraiser for the National MS Society in the U.S. She was diagnosed with MS in 2004.

About the International Progressive MS Alliance

The International Progressive MS Alliance is a first-of-its-kind global research network aimed at accelerating the development of new, effective treatments for progressive MS. We are rallying the world through an unprecedented collaboration of MS organisations, researchers, healthcare professionals, pharmaceutical companies, foundations, donors and people affected by MS. Our promise is more than hope; it is progress.

Catch-up on the previous Alliance webcasts here